Oryzon Genomics S.A.   Report issue

For profit Phase 2
Founded: Barcelona Spain (2000)

Organization Overview

First Clinical Trial
2019
NCT03867253
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Oryzon Genomics | Oryzon Genomics S.A.